Why Adaptimmune Therapeutics Is Jumping 11.5% Today

After the company announced that Japanese biopharma Astellas (OTC: ALPMY) is licensing its technology, shares in Adaptimmune Therapeutics (NASDAQ: ADAP) are rallying 11.4% at 1:45 EST on Tuesday.

Astellas will work with Adaptimmune to develop T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs derived from stem cells that can be used as off-the-shelf cancer treatments.

In exchange, Adaptimmune gets a much-needed $50 million in upfront money, up to $7.5 million annually in research funding, plus potential milestones and royalties on products developed through the collaboration.

Source Fool.com